PP2A-B56α Controls Oncogene-induced Senescence in Normal and Tumor Human Melanocytic Cells

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2011 Aug 9

PMID 21822300

Citations 27

Authors

S Mannava

A R Omilian

J A Wawrzyniak

E E Fink

D Zhuang

J C Miecznikowski

J R Marshall

M S Soengas

R C Sears

C D Morrison

M A Nikiforov

Affiliations

Soon will be listed here.

Abstract

Oncoprotein C-MYC is overexpressed in human metastatic melanomas and melanoma-derived cells where it is required for the suppression of oncogene-induced senescence (OIS). The genetic events that maintain high levels of C-MYC in melanoma cells and their role in OIS are unknown. Here we report that C-MYC in cells from several randomly chosen melanoma lines was upregulated at the protein level, and largely because of the increased protein stability. Of all known regulators of C-MYC stability, levels of B56α subunit of the PP2A tumor suppressor complex were substantially suppressed in all human melanoma cells compared with normal melanocytes. Accordingly, immunohistochemical analysis revealed that the lowest and the highest amounts of PP2A-B56α were predominantly detected in metastatic melanoma tissues and in primary melanomas from patients with good clinical outcome, respectively. Importantly, PP2A-B56α overexpression suppressed C-MYC in melanoma cells and induced OIS, whereas depletion of PP2A-B56α in normal human melanocytes upregulated C-MYC protein levels and suppressed BRAF(V600E)- and, less efficiently, NRAS(Q61R)-induced senescence. Our data reveal a mechanism of C-MYC overexpression in melanoma cells and identify a functional role for PP2A-B56α in OIS of melanocytic cells.

Citing Articles

Protein serine/threonine phosphatases in tumor microenvironment: a vital player and a promising therapeutic target.

Liu Y, Xia F, Zhu C, Song J, Tang B, Zhang B Theranostics. 2025; 15(3):1164-1184.

PMID: 39776803 PMC: 11700861. DOI: 10.7150/thno.104529.

Emerging Roles of B56 Phosphorylation and Binding Motif in PP2A-B56 Holoenzyme Biological Function.

Zhang Y, Jiang H, Yin H, Zhao X, Zhang Y Int J Mol Sci. 2024; 25(6).

PMID: 38542160 PMC: 10970375. DOI: 10.3390/ijms25063185.

Comprehensive analysis of the protein phosphatase 2A regulatory subunit B56ε in pan-cancer and its role and mechanism in hepatocellular carcinoma.

Wu H, Huang Y, Xu Y, Xiang W, Yang C, Liu R World J Gastrointest Oncol. 2024; 16(2):475-492.

PMID: 38425404 PMC: 10900161. DOI: 10.4251/wjgo.v16.i2.475.

Pleiotropy of PP2A Phosphatases in Cancer with a Focus on Glioblastoma Wildtype.

Kashani E, Vassella E Cancers (Basel). 2022; 14(21).

PMID: 36358647 PMC: 9654311. DOI: 10.3390/cancers14215227.

Molecular dissection on inhibition of Ras-induced cellular senescence by small t antigen of SV40.

Shang D, Zhou T, Zhuang X, Wu Y, Liu H, Tu Z Cell Mol Life Sci. 2022; 79(5):242.

PMID: 35429286 PMC: 11072472. DOI: 10.1007/s00018-022-04275-5.

References

Dang C, Le A, Gao P . MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009; 15(21):6479-83. PMC: 2783410. DOI: 10.1158/1078-0432.CCR-09-0889. View

Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas M, Gudkov A . c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene. 2007; 27(13):1905-15. PMC: 3144565. DOI: 10.1038/sj.onc.1210823. View

Nesbit C, Tersak J, Prochownik E . MYC oncogenes and human neoplastic disease. Oncogene. 1999; 18(19):3004-16. DOI: 10.1038/sj.onc.1202746. View

Michaloglou C, Vredeveld L, Soengas M, Denoyelle C, Kuilman T, van der Horst C . BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005; 436(7051):720-4. DOI: 10.1038/nature03890. View

Mannava S, Grachtchouk V, Wheeler L, Im M, Zhuang D, Slavina E . Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. Cell Cycle. 2008; 7(15):2392-400. PMC: 3744895. DOI: 10.4161/cc.6390. View

Eilers M . Control of cell proliferation by Myc family genes. Mol Cells. 1999; 9(1):1-6. View

Maldonado J, Fridlyand J, Patel H, Jain A, Busam K, Kageshita T . Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003; 95(24):1878-90. DOI: 10.1093/jnci/djg123. View

Shi Y, Frost P, Hoang B, Benavides A, Sharma S, Gera J . IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1. Cancer Res. 2008; 68(24):10215-22. PMC: 2701383. DOI: 10.1158/0008-5472.CAN-08-1066. View

Nikiforov M, Popov N, Kotenko I, Henriksson M, Cole M . The Mad and Myc basic domains are functionally equivalent. J Biol Chem. 2003; 278(13):11094-9. DOI: 10.1074/jbc.M212298200. View

10.

Bringold F, Serrano M . Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol. 2000; 35(3):317-29. DOI: 10.1016/s0531-5565(00)00083-8. View

11.

Bansal R, Nikiforov M . Pathways of oncogene-induced senescence in human melanocytic cells. Cell Cycle. 2010; 9(14):2782-8. PMC: 3040961. DOI: 10.4161/cc.9.14.12551. View

12.

Hann S . Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. Semin Cancer Biol. 2006; 16(4):288-302. DOI: 10.1016/j.semcancer.2006.08.004. View

13.

Wu C, van Riggelen J, Yetil A, Fan A, Bachireddy P, Felsher D . Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A. 2007; 104(32):13028-33. PMC: 1941831. DOI: 10.1073/pnas.0701953104. View

14.

Pollock P, Harper U, Hansen K, Yudt L, Stark M, Robbins C . High frequency of BRAF mutations in nevi. Nat Genet. 2002; 33(1):19-20. DOI: 10.1038/ng1054. View

15.

Larue L, Delmas V . The WNT/Beta-catenin pathway in melanoma. Front Biosci. 2005; 11:733-42. DOI: 10.2741/1831. View

16.

Zhuang D, Mannava S, Grachtchouk V, Tang W, Patil S, Wawrzyniak J . C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene. 2008; 27(52):6623-34. PMC: 3808965. DOI: 10.1038/onc.2008.258. View

17.

Welcker M, Orian A, Jin J, Grim J, Grim J, Harper J . The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A. 2004; 101(24):9085-90. PMC: 428477. DOI: 10.1073/pnas.0402770101. View

18.

Mooi W, Peeper D . Oncogene-induced cell senescence--halting on the road to cancer. N Engl J Med. 2006; 355(10):1037-46. DOI: 10.1056/NEJMra062285. View

19.

Sears R, Leone G, DeGregori J, Nevins J . Ras enhances Myc protein stability. Mol Cell. 1999; 3(2):169-79. DOI: 10.1016/s1097-2765(00)80308-1. View

20.

Hart M, de los Santos R, Albert I, Rubinfeld B, Polakis P . Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol. 1998; 8(10):573-81. DOI: 10.1016/s0960-9822(98)70226-x. View